Compare Las Vegas Sands Corp. (LVS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Smith & Nephew plc — how do they compare? Las Vegas Sands Corp. trades at $45.5 (market cap $30.36B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Las Vegas Sands Corp. is far larger — about 2.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| LVS | SNN | |
|---|---|---|
Market Cap | $30.36B | $12.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $38.70 |
52-Week Low | $44.78 | $28.73 |
Enterprise Value | $42.75B | $15.41B |
Dividend Yield | 2.4% | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.47, showing modest 0.24% daily gains amid bearish technical signals. The company demonstrates strong fundamental performance with consistent earnings beats, including Q1 2026 EPS of $0.91 exceeding expectations by 20%. Revenue growth accelerated to $13.02B in 2025, while maintaining solid profitability with 13.41% net margins. Recent corporate actions include a $0.30 dividend payment and $740M share repurchases in Q1 2026.
Analyst consensus remains strongly bullish with 61% buy ratings and $64.75 price target representing 42% upside. Key risks include high debt levels at 73.15% debt-to-asset ratio and potential regulatory headwinds in gaming markets. The combination of strong earnings momentum, attractive valuation at 16.9 P/E, and positive institutional sentiment supports a constructive outlook despite near-term technical weakness.
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
